Harvard Apparatus Regenerative Tech Inc  

(Public, NASDAQ:HART)   Watch this stock  
Find more results for JOHN F. MCNAUGHTON
1.48
-0.21 (-12.43%)
After Hours: 1.44 -0.04 (-2.70%)
Feb 8, 4:05PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.45 - 1.72
52 week 0.53 - 4.43
Open 1.69
Vol / Avg. 615,106.00/731,181.00
Mkt cap 19.49M
P/E     -
Div/yield     -
EPS -1.29
Shares 14.10M
Beta     -
Inst. own 22%
Mar 17, 2016
Q4 2015 Harvard Apparatus Regenerative Technology Inc Earnings Release (Estimated) Add to calendar
Jan 11, 2016
Harvard Apparatus Regenerative Technology Inc at EBD Biotech Showcase
Nov 12, 2015
Q3 2015 Harvard Apparatus Regenerative Technology Inc Earnings Call - Webcast
Nov 12, 2015
Q3 2015 Harvard Apparatus Regenerative Technology Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -6194.60% -11893.55%
Operating margin -6194.60% -11889.25%
EBITD margin - -11498.92%
Return on average assets -85.65% -99.34%
Return on average equity -118.33% -105.03%
Employees 24 -
CDP Score - -

Address

84 October Hill Rd Ste 11
HOLLISTON, MA 01746-1371
United States - Map
+1-774-2337300 (Phone)
+1-302-6745266 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Harvard Apparatus Regenerative Technology, Inc. is a clinical-stage biotechnology company making regenerated organs for transplant. The Company's product, the HART-Trachea, is intended to be used to restore the structure and/or function of a severely damaged trachea (windpipe). The HART-Trachea comprises the patient's own bone marrow cells seeded on the Company's InBreath porous plastic scaffold in its InBreath organ bioreactor. Its HART-Trachea addresses both of the challenges to trachea transplant, such as the shortage of suitable donor tracheas and the risk and expense of lifelong anti-rejection drug therapy. The Company has received orphan drug designation from the United States Food and Drug Administration (FDA) for the HART-Trachea in the United States market. The Company is engaged in pre-clinical development of its HART-Trachea.

Officers and directors

John F. Kennedy Chairman of the Board
Age: 66
Bio & Compensation  - Reuters
James J. McGorry President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Thomas McNaughton Jr. Chief Financial Officer
Age: 54
Bio & Compensation  - Reuters
Saverio La Francesca M.D. Executive Vice President, Chief Medical Officer
Bio & Compensation  - Reuters
David M. Green Director
Age: 50
Bio & Compensation  - Reuters
John J. Canepa Independent Director
Age: 59
Bio & Compensation  - Reuters
Thomas H. Robinson Independent Director
Age: 56
Bio & Compensation  - Reuters